[verwijderd] 29 december 2015 20:07 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 PHARMAIs Valeant Pharmaceuticals in Trouble Again?Is Valeant Pharmaceuticals in Trouble Again?Valeant seems to be in the limelight again as the CEO gets hospitalized with pneumoniaDec 29, 2015 at 9:12 am ESTIs Valeant Pharmaceuticals in Trouble Again?Design By: Rameez AhmedBy Aliya Kaleem on Dec 29, 2015 at 9:12 am EST Valeant Pharmaceutical Intl Inc. (NYSE:VRX) stock crashed by more than 10% during yesterday's trading after the company announced that CEO, J. Michael Pearson, had taken medical leave. Mr. Pearson has been diagnosed with severe pneumonia. The board has created a three-man office to lead the company temporarily.The office would include Robert Rosiello, the company's CFO, Robert Chai-Onn, General Counsel and Chief Legal Officer, and Ari Kellen, Manager, US Dermatology and Contact-lens units. Moreover, a new board committee has also been established to look over and support the executive office. The new board committee includes Robert Ingram, Valeant’s lead independent director; Howard Schiller, former chief financial officer; and Mason Morfit, president of large holder ValueAct Capital LP.The news sent the company’s stock tumbling once again, after gaining momentum after a long period of troubles. The company’s shares have been declining since the drugmaker came under the media limelight in September.Yesterday’s plunge suggests that investors aren’t satisfied by the company’s plan to reshuffle the senior management. It also indicates that it does not have a proper succession plan for Mr. Pearson, who has helped the company grow into one of the leading drugmakers in a short span of time. However, he has also faced criticisms regarding the company’s business model and the fault-finding is likely to get graver due to his illness.The company, on the other hand, believes otherwise. “Our thoughts are with Mike and his family,” Mr. Ingram said in a statement announcing Mr. Pearson’s medical leave on Monday. “I am confident that with the vast industry and business knowledge from the management team and the board of directors, we will manage through this period.”Mr. Pearson was admitted to a hospital in New Jersey last week, source familiar with the matter told The Wall Street Journal. He was later shifted to another hospital where he would receive more sophisticated treatment.The absence of the CEO seems to be troubling investors. The company had been under pressure lately due to several criticisms revolving around its business model, ethics and drug prices. The troubles began in September, when the company came under fire for its horrendous price increments. Democrat candidate Hillary Clinton especially brought attention to the fact that drugmakers were acquiring proven and undervalued drugs and increasing their prices by several folds to wring out maximum profits.As political pressure regarding the exorbitant prices increased, Citron published a report bringing a specialty pharmacy, Philidor, into the frame. The report questioned Valeant’s relationship with the pharmacy and also accused Philidor of altering doctors' prescriptions in favor of Valeant’s drugs to extract more reimbursements from health payers.The report sent the company’s shares tumbling down by almost 20% in a day. Valeant was accused of being an Enron-like fraud by the Citron report, leading to a loss of investor-confidence in the company and its management. Philidor only dealt in Valeant’s drugs, specifically its expensive dermatology products.Meanwhile, criticism over Valeant and Philidor's relationship kept heating up. Investors and analysts started speculating if Valeant had other pharmacies, which were working on the Philidor model. It was also discovered that Philidor was mainly run by Valeant’s ex-employees. Sources reported that the two parties maintained close ties, while Valeant claimed otherwise.As criticism mounted, Valeant announced that Philidor would wind up its operations as soon as possible. The decision came as a bit of surprise and suggested that Valeant would suffer a dent in sales from its dermatology portfolio, impacting the company’s overall sales growth as well.As the company’s stock hit rock bottom prices, Bill Ackman acquired a massive chunk of Valeant stock. Mr. Ackman’s hedge fund, Pershing Square, was already one of the largest shareholders of Valeant and has always shown confidence in the company and its model.Investors also raised eyebrows on the company’s debt load. Valeant currently has a debt of more than $30 billion, while its cash flows do not seem quite enough to pay off the debt.However, after a prolonged period of controversies, the company announced a positive step. Earlier this month, Valeant announced that it had signed a distribution pact with Walgreens Boot Alliance, under which, Walgreens would be distributing Valeant’s dermatology and ophthalmology products. It was also announced that the drugs would be sold at some specified discount."We have listened to what the marketplace is saying and we've taken positive steps to respond. We are pleased to announce both a strategic fulfillment agreement with Walgreens, as well as a new agreement to offer innovator products at generic prices, which is good for consumers, good for physicians and good for the healthcare system," said Mr. Pearson in the company’s statement. "Our goal is to create a system that allows prescription medications to be dispensed and insurance claims adjudicated in an efficient manner while allowing physicians to focus their efforts on what matters most: patient care."The actual deal was more complicated than it sounds, and this seems to be a key concern for investors. Valeant stock had declined to $80 per share, but Mr. Pearson was able to drive it above the $110 level. With the CEO on the rest, investors seem not quite sure if the executives’ office would be able to execute the new deal, which is currently very crucial to the drugmaker’s future. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 29 december 2015 20:08 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 TICS (NYSEMKT:MSTX)healthcare-sectorHEALTH CAREBUY, SELL OR HOLD THREE HEALTHCARE STOCKS??? VALEANT PHARMACEUTICALS INTL INC (NYSE:VRX), BOSTON SCIENTIFIC (NYSE:BSX), MAST THERAPEUTICS (NYSEMKT:MSTX)December 29, 2015 By Marry Johnson 0 39Valeant Pharmaceuticals Intl Inc (NYSE:VRX) showed bearish trend with lower momentum of -10.45% to close at $102.18. The company traded total volume of 15.44 million shares as compared to its average volume of 12.07 million shares. The company has a market value of $38.94 billion and about 341.19 million shares outstanding. During the 52-week trading session the minimum price at which share price traded, registered at $69.33 and reached to max level of $263.81.Analyst rating:During the current month, Wall Street analysts gave the rating about the company shares whether it is time to BUY, SELL or HOLD the shares. “9” analyst said that BUY the stock and Strong BUY signal was issued by “5” analysts. Sell rating was given by “0” analysts. Hold signal was recommended by “7” analysts. Underperform rating was given by “1” analyst.Valeant Pharmaceuticals International, Inc. (VRX) (VRX) reported that chairman and chief executive officer J. Michael Pearson will be on a medical leave of absence, effective immediately. The company’s board of directors has created an Office of the Chief Executive Officer, which will include Robert Chai-Onn, Executive Vice President and General Counsel, Dr. Ari Kellen, Executive Vice President and FirmGroup Chairman, and Robert Rosiello, Executive Vice President and Chief Financial Officer, to serve in an interim capacity. In addition, the Board of Directors has created a Committee to oversee and support the Office of the CEO and will include Robert A. Ingram, Lead Independent Director, G. Mason Morfit, President, ValueAct Capital, and Howard B. Schiller, former Chief Financial Officer for Valeant.Boston Scientific Corporation (NYSE:BSX) began its trading session at $18.64 on Monday. During the most recent trading session the minimum price at which share price traded, recorded at $18.48 and hit to max level of $18.74. The company rose 0.01 points or 0.05%. The company finished it trading session at 18.73. The company has market worth of $25.18 billion. It traded total volume of 3.30 million shares lower than the average volume of 8.35 million shares.Analyst rating:During the current month, Wall Street analysts gave the rating about the stock whether it is time to BUY, SELL or HOLD the stock. “14” analyst said that BUY the stock and Strong BUY signal was issued by “8” analysts. Sell rating was given by “0” analysts. Hold signal was recommended by “5” analysts. Underperform rating was given by “0” analysts.Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.Shares of Mast Therapeutics Inc (NYSEMKT:MSTX) finished up 2.52% to close at $0.411. The stock kicked off the day at $0.40 and traded between a low of $0.40 and a high of $0.43. The company traded 2.22 million shares more than average volume of 1.31 million shares. The stock’s worth is $65.53 million.Analyst rating:During the current month, Wall Street analysts gave the rating about the company shares whether it is time to BUY, SELL or HOLD the shares. “5” analyst said that BUY the stock and Strong BUY signal was issued by “1” analyst. Sell rating was given by “0” analysts. Hold signal was recommended by “0” analysts. Underperform rating was given by “0” analysts.Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for serious or life-threatening diseases. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 11 januari 2016 20:30 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 @jager kijk bluebird eens gaan pffffffffff Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 11 januari 2016 20:51 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Ja, toevallig heb ik die gisteren verkocht. Puur mazzel, maar wat dacht je van VRX, Applied DNA en Intercloud. Daar zit ik nog wel in. Niet makkelijk om op tijd je winst te pakken Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 11 januari 2016 21:03 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 idd ik zit er ook diep in qua porto maar ws bedoel je afgelopen vrijdag verkocht.ik zit wel te lonken naar bleubird,vrx,bleubird ,aapl,en icld zijn mijn favorieten ik houd ogen open heb vorige week wel een succesvol ritje gemaakt met catb 7.10 naar 7.40 Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 11 januari 2016 22:16 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Hoewel het pure gok aandelen zijn, toch nog maar wat BLUEBIRD aangeschaft. En het was natuurlijk vrijdag. Intercloud ben ik een beetje huiverig voor. Heb er nog genoeg. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 12 januari 2016 15:34 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Iemand enig idee wat er nu aan de hand is met Intercloud?Gaat nu wel heel hard down elke dag.... Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 12 januari 2016 18:16 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 ingestapt in intercloud op 0,67waarom deze daling, volume is redelijk normaal Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 12 januari 2016 19:03 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Heb ze aangeschaft boven 1 euro, dus dat ziet er niet best uit. Aandeel kan ook zo maar 10 tot 20% herstellen. De reden van deze afwaardering is me niet duidelijk. De sector staat wereldwijd onder grote druk. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 12 januari 2016 19:52 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 InterCloud Systems Closes Out 2015 With New Contracts Valued at Over $2.3 MillionSecures New Financing of $7.5 Million PrintJanuary 08, 2016 09:38 ET | Source: InterCloud Systems, Inc.NEW YORK, Jan. 08, 2016 (GLOBE NEWSWIRE) -- InterCloud Systems, Inc. (the "Company" or "InterCloud") (NASDAQ:ICLD), a leading provider of cloud networking orchestration and automation solutions and services, today announced that during the last few weeks of the calendar year it was awarded over $2.3 million in new contracts for professional and managed services, as well as for the deployment of InterCloud’s DPoD, hyper-converged private cloud solution. All of these services are expected to begin shortly.Mark Munro, CEO of InterCloud Systems stated: "Our sales organization closed out its best year ever with several large new contracts and over $7M in cash. Throughout the last twelve months our revenue and adjusted EBITDA growth has been significant over 2014. Management made tremendous strides during 2015 in integration savings, new industry leading cloud products and services rollouts, and several significant contract wins with some of the world's largest carriers. Our pipeline of sales opportunities remains at an all time high of over $149,000,000 and we have maintained a significant backlog of business to carry us into an exciting 2016. Our plans are to continue to build our cloud sales pipeline and backlog of recurring revenue. We have seen a major shift in enterprise and carrier customers willingness to deploy private cloud solutions with SDN (software defined network) and NFV (network function virtualization) at their core. The momentum is far greater than it was at the beginning of 2015 and our team is prepared to take advantage of this growth market this year and beyond."About InterCloud Systems, Inc.InterCloud Systems, Inc. is a leading provider of cloud networking orchestration and automation, for Software Defined Networking (SDN) and Network Function Virtualization (NFV) cloud environments to the telecommunications service provider (carrier) and corporate enterprise markets through cloud solutions and professional services. InterCloud's cloud solutions offer enterprise and service-provider customers the opportunity to adopt an operational expense model by outsourcing cloud deployment and management to InterCloud rather than the capital expense model that has dominated in recent decades in IT infrastructure management. Additional information regarding InterCloud may be found on InterCloud's website at www.intercloudsys.com.Forward-looking statements:The above news release contains forward-looking statements. The statements contained in this document that are not statements of historical fact, including but not limited to, statements identified by the use of terms such as "anticipate," "appear," "believe," "could," "estimate," "expect," "hope," "indicate," "intend," "likely," "may," "might," "plan," "potential," "project," "seek," "should," "will," "would," and other variations or negative expressions of these terms, including statements related to expected market trends and the Company's performance, are all "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performances, and are subject to a wide range of external factors, uncertainties, business risks, and other risks identified in filings made by the company with the Securities and Exchange Commission. Actual results may differ materially from those indicated by such forward-looking statements. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based except as required by applicable law and regulations. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 12 januari 2016 19:59 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 dat leek me ook een goed bericht vandaar ingestapt op 0,67had goedkoper gekunt Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 12 januari 2016 22:09 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Toch nog een ritje kunnen maken van 0,56 naar 0,65. Er zit dus nog muziek in. Morgen waarschijnlijk weer hoger. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 12 januari 2016 22:27 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Lijkt net werken de laatste dagen. Je moet er bovenop zitten om een paar centen te verdienen. Maar ik doe het graag! Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 13 januari 2016 00:06 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Ook de BLUEBIRDS met winst weer laten vliegen! Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 13 januari 2016 06:31 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 nabeurs 0,69 na open briefwww.streetinsider.com/Corporate+News/...wie weet helpt dit de koers verder richting 1 usd Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 13 januari 2016 14:34 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 voorbeurs 0,74 Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 13 januari 2016 15:40 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 verkocht 0,8120% binnen 24hsucces allen Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 13 januari 2016 16:31 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:Jager63 schreef op 12 januari 2016 22:09:Toch nog een ritje kunnen maken van 0,56 naar 0,65. Er zit dus nog muziek in. Morgen waarschijnlijk weer hoger.Klopt was te vroeg. In de laatste minuten van de beurs. Net bij opening de andere helft op 0,99 verkocht. Dat zijn nog eens bewegingen. Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 13 januari 2016 17:39 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Henk, je vertrouwen wordt beloond! Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 13 januari 2016 18:11 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 teruggekocht 0,72 Aanbevelingen 0 ” Quote Reageren Niet oké
Beurscodes, betekenis en hulp bij zoeken Europa AEX Euronext Amsterdam BRU Euronext Brussels PSE Euronext Paris LIS Euronext Lissabon CHX CBOE Europe, grote(re) EU aandelen NAV Investment Funds (NAV) Noord-Amerika NYS New York Stock Exchange OTC CBOE BZX Exchange (US) TSE Toronto Stock Exchange Kunt u een instrument niet vinden? Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code. Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze. Waar vind ik die ISIN code? Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'. Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.